Literature DB >> 11916315

Outcome of tyrosinaemia type III.

C J Ellaway1, E Holme, S Standing, M A Preece, A Green, E Ploechl, M Ugarte, F K Trefz, J V Leonard.   

Abstract

Tyrosinaemia type III is a rare disorder caused by a deficiency of 4-hydroxyphenylpyruvate dioxygenase, the second enzyme in the catabolic pathway of tyrosine. The majority of the nine previously reported patients have presented with neurological symptoms after the neonatal period, while others detected by neonatal screening have been asymptomatic. All have had normal liver and renal function and none has skin or eye abnormalities. A further four patients with tyrosinaemia type III are described. It is not clear whether a strict low tyrosine diet alters the natural history of tyrosinaemia type III, although there remains a suspicion that treatment may be important, at least in infancy.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11916315     DOI: 10.1023/a:1013936107064

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  11 in total

Review 1.  Neurochemistry and defects of biogenic amine neurotransmitter metabolism.

Authors:  K Hyland
Journal:  J Inherit Metab Dis       Date:  1999-06       Impact factor: 4.982

2.  Tyrosinemia type III: diagnosis and ten-year follow-up.

Authors:  R Cerone; E Holme; M C Schiaffino; U Caruso; L Maritano; C Romano
Journal:  Acta Paediatr       Date:  1997-09       Impact factor: 2.299

3.  Autoimmune thyroiditis in a case of tyrosinaemia type III.

Authors:  P D'Eufemia; O Giardini; A Cantani; F Martino; R Finocchiaro
Journal:  J Inherit Metab Dis       Date:  1992       Impact factor: 4.982

4.  Chronic tyrosinemia associated with 4-hydroxyphenylpyruvate dioxygenase deficiency with acute intermittent ataxia and without visceral and bone involvement.

Authors:  O Giardini; A Cantani; N G Kennaway; P D'Eufemia
Journal:  Pediatr Res       Date:  1983-01       Impact factor: 3.756

5.  Immunological abnormalities in a patient with tyrosinaemia type III.

Authors:  P D D'Eufemia; R Finocchiaro; M Celli; L Viozzi; O Giardini
Journal:  J Inherit Metab Dis       Date:  1995       Impact factor: 4.982

6.  Hereditary tyrosinemia type I: a new clinical classification with difference in prognosis on dietary treatment.

Authors:  F J van Spronsen; Y Thomasse; G P Smit; J V Leonard; P T Clayton; V Fidler; R Berger; H S Heymans
Journal:  Hepatology       Date:  1994-11       Impact factor: 17.425

7.  Mutations in the 4-hydroxyphenylpyruvic acid dioxygenase gene are responsible for tyrosinemia type III and hawkinsinuria.

Authors:  K Tomoeda; H Awata; T Matsuura; I Matsuda; E Ploechl; T Milovac; A Boneh; C R Scott; D M Danks; F Endo
Journal:  Mol Genet Metab       Date:  2000-11       Impact factor: 4.797

8.  Mutations in the 4-hydroxyphenylpyruvate dioxygenase gene (HPD) in patients with tyrosinemia type III.

Authors:  U Rüetschi; R Cerone; C Pérez-Cerda; M C Schiaffino; S Standing; M Ugarte; E Holme
Journal:  Hum Genet       Date:  2000-06       Impact factor: 4.132

9.  Four-hydroxyphenylpyruvic acid oxidase deficiency with normal fumarylacetoacetase: a new variant form of hereditary hypertyrosinemia.

Authors:  F Endo; A Kitano; I Uehara; N Nagata; I Matsuda; T Shinka; T Kuhara; I Matsumoto
Journal:  Pediatr Res       Date:  1983-02       Impact factor: 3.756

Review 10.  Abnormalities of biogenic amine metabolism.

Authors:  K Hyland
Journal:  J Inherit Metab Dis       Date:  1993       Impact factor: 4.982

View more
  20 in total

1.  Neurocognitive outcome in patients with hypertyrosinemia type I after long-term treatment with NTBC.

Authors:  Eva Thimm; Renate Richter-Werkle; Gudrun Kamp; Bettina Molke; Diran Herebian; Dirk Klee; Ertan Mayatepek; Ute Spiekerkoetter
Journal:  J Inherit Metab Dis       Date:  2011-11-09       Impact factor: 4.982

Review 2.  Amino acid disorders.

Authors:  Ermal Aliu; Shibani Kanungo; Georgianne L Arnold
Journal:  Ann Transl Med       Date:  2018-12

Review 3.  Old treatments for new insights and strategies: proposed management in adults and children with alkaptonuria.

Authors:  Jean-Baptiste Arnoux; Kim-Hanh Le Quan Sang; Anais Brassier; Coraline Grisel; Aude Servais; Julien Wippf; Sandrine Dubois; Nicolas Sireau; Chantal Job-Deslandre; Lakshminarayan Ranganath; Pascale de Lonlay
Journal:  J Inherit Metab Dis       Date:  2015-04-10       Impact factor: 4.982

4.  Nitisinone in the treatment of hereditary tyrosinaemia type 1.

Authors:  Patrick J McKiernan
Journal:  Drugs       Date:  2006       Impact factor: 9.546

Review 5.  New developments in ochronosis: review of the literature.

Authors:  Julie M Keller; William Macaulay; Ohannes A Nercessian; Israeli A Jaffe
Journal:  Rheumatol Int       Date:  2004-08-21       Impact factor: 2.631

6.  Ophthalmic follow-up of patients with tyrosinaemia type I on NTBC.

Authors:  P Gissen; M A Preece; H A Willshaw; P J McKiernan
Journal:  J Inherit Metab Dis       Date:  2003       Impact factor: 4.982

7.  NTBC treatment in tyrosinaemia type I: long-term outcome in French patients.

Authors:  A Masurel-Paulet; J Poggi-Bach; M-O Rolland; O Bernard; N Guffon; D Dobbelaere; J Sarles; H Ogier de Baulny; G Touati
Journal:  J Inherit Metab Dis       Date:  2008-01-25       Impact factor: 4.982

Review 8.  Alkaptonuria.

Authors:  Jemma B Mistry; Marwan Bukhari; Adam M Taylor
Journal:  Rare Dis       Date:  2013-12-18

9.  Tyrosine administration decreases glutathione and stimulates lipid and protein oxidation in rat cerebral cortex.

Authors:  Angela M Sgaravatti; Alessandra S Magnusson; Amanda S de Oliveira; Andréa P Rosa; Caroline Paula Mescka; Fernanda R Zanin; Carolina D Pederzolli; Angela T S Wyse; Clóvis M D Wannmacher; Moacir Wajner; Carlos Severo Dutra-Filho
Journal:  Metab Brain Dis       Date:  2009-08-18       Impact factor: 3.584

Review 10.  Ochronotic arthropathy as a paradigm of metabolically induced degenerative joint disease. A case-based review.

Authors:  L Ventura-Ríos; C Hernández-Díaz; L Gutiérrez-Pérez; A Bernal-González; R Pichardo-Bahena; A L Cedeño-Garcidueñas; C Pineda
Journal:  Clin Rheumatol       Date:  2014-03-20       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.